Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05858463
Other study ID # AOI 2022 COSTES
Secondary ID 2022-A02468-35
Status Recruiting
Phase N/A
First received
Last updated
Start date September 2023
Est. completion date September 2025

Study information

Verified date March 2023
Source University Hospital, Clermont-Ferrand
Contact Lise LACLAUTRE
Phone +33473754963
Email promo_interne_drci@chu-clermontferrand.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pulmonary rehabilitation (PR) is a validated treatment in patients with Chronic Obstructive Pulmonary Disease (COPD), improving exercise tolerance, quality of life and dyspnea. However, 20 to 30% of patients did not respond to PR and particularly those with chronic hypoxaemia. In most disabled patients, High Intensity Interval training (HIIT) is an alternative to perform exercise training with similar gain in exercise capacity than continuous exercise training. In patients with exercise-induced oxygen desaturation, the repetitions of hypoxia/resaturation phases during intermittent exercise could result in bursts of oxidative stress and induce positive or detrimental effect on mitochondrial function according to the importance in the oxidant stimulus. Few data have ascertained the benefit of HIIT on mitochondrial oxidative capacity (Vmax) in healthy subjects compared to continuous exercise training but no data are available in COPD patients with exercise-induced desaturation, and the change in oxidative stress in such training regimen. The investigators hypothesize that the repetitive bursts of oxidative stress and the improved antioxidant capacity in the course of the training sessions would stimulate mitochondrial adaptations to a larger extent after HIIT than continuous exercise training in severe COPD patients with hypoxemia. Moreover, they will assess the relationship between the change in oxidative stress in blood and in muscle. The clinical relevance of this study will be to ascertain the benefit and the safety of HITT in this subgroup of COPD patients in whom benefit of PR is often weak.


Description:

The investigators will conduct an open-label randomized controlled trial in 2 parallel groups of COPD patients referred for a pulmonary rehabilitation programme (PR). After inclusion the patients will be randomized in HIIT (IG) or continuous groups (CG). Two visits will be planned before and 2 immediately after completion of PR, with similar tests. 1. A cycling endurance test performed until exhaustion CG: exercise at 75% of predetermined maximal workload (Wmax) IG: 1 min at Wmax followed with 1 min unloaded pedaling, up to a maximal duration of 30 minutes. During this test, oxygen consumption, minute ventilation, cardiac output (thoracic impedance), pulse oxygen saturation and muscle oxygen saturation (NIRS) will be recorded continuously. Markers of oxidative stress will be measured before and at the end of the cycling test (5 ml blood). 2. The mitochondrial oxidative capacity of the quadriceps will be measured on a separate day. A 20 mg biopsy of the vastus lateralis will be obtained under local anaesthesia using a biopsy needle. Maximal mitochondrial oxygen consumption (Vmax) will be measured on fresh permeabilized fibers (10 mg) using high resolution respirometry (Oroboros®), and 10 mg will be frozen for determination of oxidative markers. Vmax was also determined non invasively by the recovery of muscle oxygen saturation (NIRS) during repetitive brief arterial occlusions (according to the method described by Ryan and coll). As part of PR, the participants will complete 20 sessions of exercise training (HIIT or continuous). The exercise intensity will be adapted weekly according to the participant's sensation. In the IG, the sessions will not exceed 40 min (20 min of active exercise).


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 2025
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - COPD diagnosed according to Global Obstructive Lung Diagnosis criteria; no exacerbation of COPD in the last month - Referred for a pulmonary rehabilitation program - Exercise-induced oxygen desaturation during a CardioPulmonary Exercise Test, defined as a decrease of oxygen saturation by pulse oximetry >4% from resting value. - Written informed consent - Negative pregnancy test whenever applicable. Exclusion Criteria: - Acute exacerbation of COPD during the last 4 weeks - Physical or psychological inability to perform exercise tests - Life-threatening cardiac events contra-indicating exercise training - Anticoagulant treatment (muscle biopsy) - Pregnant or breastfeeding womenFemmes - Subject with curator, deprived of freedoms or in safeguard of justice - Non covered by the french social security system

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Modality of exercise training
muscle adaptations following intermittent high intensity interval exercise training and continuous low intensity exercise training

Locations

Country Name City State
France CHU de Clermont-Ferrand Clermont-Ferrand

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vmax variation variation of maximal mitochondrial O2 consumption ( pmol O2.s-1.mg-1) ( with exercise training in both groups from the beginning to the end of the exercise training program (maximum duration 3 months)
Secondary blood oxidative stress variation variation with exercise training in both groups of blood oxidative stress, with a composite score obtained by the plasmatic levels of superoxide dismutase, gluthation peroxydase, xanthine oxidase, catalase and myeloperoxidase from the beginning to the end of the exercise training program (maximum duration 3 months)
Secondary mVO2 variation variation of muscle oxidative capacity measured by NIRS(affinity constant, min-1) with exercise training in both groups from the beginning to the end of the exercise training program (maximum duration 3 months)
Secondary Cardiac output variations variations with exercise training in both groups of cardiac output (L.min-1) measurements during endurance cycling exercise from the beginning to the end of the exercise training program (maximum duration 3 months)
Secondary Respiratory variations variations with exercise training in both groups of minute ventilation (L.min-1) measurements during endurance cycling exercise from the beginning to the end of the exercise training program (maximum duration 3 months)
Secondary muscle oxygen variations variations with exercise training in both groups of tissue index oxygenation (TIO,%) measured by Near Infrared Spectroscopy during endurance cycling exercise from the beginning to the end of the exercise training program (maximum duration 3 months)
See also
  Status Clinical Trial Phase
Completed NCT05043428 - The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD N/A
Completed NCT00528996 - An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler. Phase 2
Completed NCT03740373 - A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate Phase 1
Completed NCT05402020 - Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
Completed NCT05393245 - Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
Completed NCT04011735 - Re-usable Respimat® Soft MistTM Inhaler Study
Enrolling by invitation NCT03075709 - The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
Completed NCT03764163 - Image and Model Based Analysis of Lung Disease Early Phase 1
Completed NCT00515268 - Endotoxin Challenge Study For Healthy Men and Women Phase 1
Completed NCT04085302 - TARA Working Prototype Engagement Evaluation: Feasibility Study N/A
Completed NCT03691324 - Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study N/A
Completed NCT02236611 - A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT00153075 - Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT01009463 - A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT01017952 - A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT04882124 - Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD Phase 2
Completed NCT02853123 - Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients Phase 4
Completed NCT02619357 - Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma Phase 1
Not yet recruiting NCT05032898 - Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
Completed NCT02837380 - A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects Phase 1